drugset
drugset / Trial / NCT01007019

Safety/Tolerability and Pharmacokinetics/Pharmacodynamics of YH4808 After Oral Administration in Healthy Male Subjects

NCT01007019 ↗

Phase 1 Completed 134 enrolled Yuhan Corporation
RandomizedParallel-groupDouble-blindBasic science

Summary

First in human study

Timeline

Start
2009-11
Primary completion
2011-03
Completion
2012-03

Drugs

EvaluationDrugModalityDoseRoute
Comparator Esomeprazole Small molecule 40 mg —
Subject YH4808 Other / unclassified 30 mg Oral
Subject YH4808 Other / unclassified 50 mg Oral
Subject YH4808 Other / unclassified 100 mg Oral
Subject YH4808 Other / unclassified 200 mg Oral
Subject YH4808 Other / unclassified 400 mg Oral
Subject YH4808 Other / unclassified 600 mg Oral
Subject YH4808 Other / unclassified 800 mg Oral

Indications

No indication recorded.